The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study).
Setting: France, 17 Hospital sites
Follow up: 6 months
Total: 180 (173)
IG1: 60 (56)
IG2: 59 (57)
CG: 61 (60)
- Diabetes type 1
- HbA1c ≥ 8.0%
App “electronic logbook” (Diabeo)
- Feedback on data (algorithms)
- Data transmission to medical staff
IG1: Electronic logbook but no teleconsultation. Face to face follow up at 3 and 6 months.
IG2: Electronic logbook and teleconsultations (phone call) every 2 week. Teleconsultations were focused on insulin dose adjustments and motivational support.
Duration: 6 months
Add on: –
Control group: No electronic logbook/app, follow up visits at hospital after 3 and 6 months.
- HbA1c: IG1 ↓ and IG2↓
- HBA1c ≤ 7.5%: IG1 → and IG2↓
- QOL: IG1→ and IG2→
Patient safety: No difference in the frequency of symptomatic, nonsevere hypoglycemia episodes.
- 73% (IG2) stated that they wanted to continue with the app.
- Time spend on travelling to hospital, administrative procedures, and waiting time:
CG: 274 min
- Doctors average time spend on consultations
IG2=72 min (tele)
- Mean number of teleconsultations: 8.7
- Mean duration for one teleconsultation: 7.4 min.
- Blood glucose
- Blood pressure
- Test strips (glucose)
- Staff for monitoring and phonecalls/sms
Health care utilization: NA